Cannabinoid Family Related Drug Discovery Products
Creative Biolabs has the assays you can rely on for high throughput screening, lead optimization, characterizing and discovering targets, and uncovering the complexity of disease pathways. We can offer membrane protein in vitro assay kits that save valuable laboratory time and is ideal for high throughput screening.
Membrane protein stable cell lines are widely used in many areas of biomedical research. Creative Biolabs can offer membrane protein stable cell lines to stablish in vitro models for High Throughput Screening.
Creative Biolabs offers high-quality, innovative tools to help research groups accelerate membrane protein drug discovery. They can be found by targets. If there is no product that meets your needs, please contact us.
The central and peripheral nerve systems both contain the endocannabinoid system (ECS), a sophisticated lipid signaling mechanism. It has two cannabinoid receptors (CB1Rs and CB2Rs). Since the discovery of ECS, there has been a significant interest in creating medications that specifically target CB1Rs and CB2Rs. In fact, CBRs offer tremendous promise as a therapeutic target for a variety of diseases. CB1Rs are widely distributed, mostly in the CNS but also in non-neuronal tissues, peripheral nerve terminals, and the CNS itself. Numerous illnesses, including obesity, mental illness, pain, multiple sclerosis, and drug addiction, are linked to CB1Rs. There are just a few CNS regions where CB2Rs are expressed. They are mostly present in immune cells, where they control cytokine release and cell movement.
Creative Biolabs offers a range of cannabinoid family tools with our well-established high-efficient drug discovery strategy in a timely and cost-effective manner:
Overview of Cannabinoid Receptor
The GPCRs known as brain cannabinoid (CB1) receptors are members of the rhodopsin-like subfamily. Gi/o proteins interact with CB1 receptors to inhibit adenylyl cyclase and activate mitogen-activated protein kinases during signal transduction (MAPK). It is generally known that CB1 receptors have an impact on memory and learning, and illness states linked to CB1 receptors include schizophrenia, bipolar disorder, motor dysfunction, addiction disorders, and bipolar, depression, and anxiety disorders.
Several recent evaluations have placed a major emphasis on the possible utility of CB2 receptor agonists. In addition to its function in the cellular immune system, the CB2 receptor has emerged as a desirable target for the development of new drugs in conditions as diverse as osteoporosis, atherosclerosis, and chronic pain. Recent research has also shown promise for CB2 receptor-specific ligands in the treatment of cancer, particularly immune system malignancies.
Fig.1 The CB2 cannabinoid receptor is associated with distinct pathophysiologies. (Gertsch, 2006)
Cannabinoid Receptor Drug Discovery
Because they play a role in both physiological and pathological processes, CBRs provide for interesting drug discovery targets. The initial goal of the research was to create orthosteric ligands that interact with the endogenous cannabinoids' active site. However, this method failed to convert CBRs orthosteric ligands into druggable candidates, mostly because of the negative side effects connected to CBRs orthosteric ligands. Many chemicals have been identified as CB1R allosteric modulators, while only a small number of substances have been found to be CB2R allosteric modulators. Due to their many advantages over orthosteric ligands, such as their excellent receptor type selectivity, dependency on probes, and lack of impact on EC activity, CBRs allosteric modulators are particularly attractive drugs.
Reference
- Gertsch, J.; et al. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. Journal of Receptors and Signal Transduction. 2006, 26(5-6): 709-730.
